share_log

Cantor Fitzgerald Reiterates Overweight on Mirum Pharmaceuticals, Maintains $35 Price Target

Cantor Fitzgerald Reiterates Overweight on Mirum Pharmaceuticals, Maintains $35 Price Target

坎托·菲茨杰拉德重申增持Mirum Pharmicals,维持35美元的目标股价
Benzinga ·  02/29 13:36

Cantor Fitzgerald analyst Josh Schimmer reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and maintains $35 price target.

坎托·菲茨杰拉德分析师乔什·希默重申米鲁姆制药公司(纳斯达克股票代码:MIRM)增持,目标股价维持35美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发